8-K: Monogram Technologies Announces Strategic Clinical Trial Collaboration with Shalby Limited

Monogram Technologies has partnered with Shalby Limited for a multicenter clinical trial of its mBs TKA System, marking a significant step towards international expansion.

Summary

• Monogram Technologies Inc. has announced a strategic collaboration with Shalby Limited, a leading global orthopedic hospital chain, to conduct a multicenter clinical trial for the mBs TKA System.
• Shalby is the largest orthopedic hospital chain in the world by volume of arthroplasty, with 14 hospitals in 13 cities and treating over 3 million patients.
• The clinical trial will evaluate the safety and effectiveness of the mBs TKA System using the Consensus CKS implant, which is substantially equivalent to Monogram's mPress implants.
• Monogram submitted its 510(k) application to the FDA on July 19, 2024, which has passed the FDA Administrative Review.
• The collaboration includes the potential transfer of a robot to Shalby after the trial, and further studies on next-generation solutions are expected.
• Shalby represents approximately 15% of the organized arthroplasty market in India, which has an approximate market size of 200,000 TKAs per year with a 20% compound annual growth rate.
• Monogram plans to use the clinical data from the US study for post-launch marketing and international commercialization.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic collaboration, progress with FDA, and the potential for international expansion. The partnership with a major player like Shalby is a strong positive signal.

Positives

• The collaboration with Shalby provides Monogram access to a large network of experienced surgeons and a significant market for its technology.
• The clinical trial is a crucial step towards international commercialization of the mBs TKA System.
• Passing the FDA Administrative Review for the 510(k) application is a positive milestone.
• Shalby's growth rate of 20% CAGR over fifteen years indicates a strong and expanding partner.
• The potential transfer of a robot to Shalby post-trial suggests a strong commitment to the partnership.

Negatives

• The document mentions that Monogram cannot estimate the timing or assure the ability to obtain FDA clearances, which introduces uncertainty.
• The company is still in the process of obtaining FDA clearance for its robotic products, which is a risk to commercialization.

Risks

• The company's ability to obtain FDA clearance for its robotic products is not guaranteed.
• The success of the clinical trial is crucial for the commercialization of the mBs TKA System.
• The company's future performance is subject to various risks and uncertainties, as detailed in their SEC filings.

Future Outlook

Monogram plans to leverage the clinical data from the US study for post-launch marketing and to support international clearance and commercialization. The companies expect the relationship to extend, with additional studies on next-generation solutions like mVision to follow.

Management Comments

• Dr. Vikram Shah, Chairman of Shalby, stated that Shalby aspires to become a top 10 player in orthopedics globally within the next decade.
• Dr. Shah believes that Monogram's technology could change the face of orthopedic medicine forever.
• Ben Sexson, CEO of Monogram Technologies Inc., believes that India represents a massive market potential for their system.
• Ben Sexson stated that the recent 510(k) submission and passing of the FDA Administrative Review is a catalyst for strategic synergies.

Industry Context

This collaboration highlights the growing trend of using advanced robotics and AI in orthopedic surgery. It also reflects the increasing importance of the Indian market for medical device companies, given its large population and growing healthcare sector.

Comparison to Industry Standards

• Shalby is a major player in the global orthopedic market, performing over 14,000 knee replacements annually, which is comparable to other large orthopedic groups such as Stryker, Zimmer Biomet, and Johnson & Johnson's DePuy Synthes.
• The Indian arthroplasty market's 20% CAGR is significantly higher than the global average, indicating a high growth potential compared to mature markets in North America and Europe.
• Monogram's focus on AI-driven robotics aligns with the industry's move towards personalized and precision medicine, similar to companies like Smith+Nephew and Medtronic who are also investing in robotic surgery.

Stakeholder Impact

• Shareholders may view this collaboration positively due to the potential for revenue growth and market expansion.
• Employees may see this as a positive development for the company's growth and future opportunities.
• Customers (surgeons and hospitals) may benefit from access to advanced robotic technology.
• Suppliers may see increased demand for components and materials.
• Creditors may view this as a positive development for the company's financial stability.

Next Steps

• Conduct a multicenter clinical trial in India to evaluate the safety and effectiveness of the mBs TKA System.
• Potentially transfer a robot to Shalby after the trial.
• Conduct additional studies on next-generation solutions like mVision.
• Leverage clinical data for post-launch marketing and international commercialization.

Key Dates

Keywords

orthopedic surgery, robotics, clinical trial, knee replacement, mBs TKA System, Shalby Limited, FDA clearance, arthroplasty, medical devices, AI